OPXA is currently focused on secondary progressive MS (SPMS) as its first priority, which represents a change from the prior (longer, and more expensive development path) relapse-remitting MS (RRMS). This is a logical move as RRMS is more difficult to measure because it relapses. The SPMS market is 25 - 50% of the overall MS market. My DD indicates the total addressable north american market (the only region where OPXA has established logistics for T-cell extraction) for SPMS is US$ 3b. Of this 3b, because of the low degree of currently available therapies, (only one qualified to-date), my assumption for penetration (after commercialization, which is at a minimum, still years away) is:
* first full fiscal year of commercialization 25% of addressable market or $750m,
* second year $937m (assuming 25% CAGR).
Market Data 
Markets 
AI
